Please login to the form below

Not currently logged in
Email:
Password:

Dr Catherine Strader joins Acorda Therapeutics’ board

She brings experience from Merck & Co and Synergy Partners R&D Solutions

Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader.

Dr Strader is currently a founding partner at Synergy Partners R&D Solutions, and prior to co-founding the drug discovery and development network in 2014 was vice president and discovery site head at Merck & Co's New Jersey hub.

She also brings executive leadership experience from Schering-Plough, where she served as executive vice president of discovery research and chief scientific officer between 2002 and 2007.

Dr Ron Cohen, Acorda's president and chief executive officer, said: “Catherine brings decades of experience as both a drug developer and biopharmaceutical business executive with an outstanding track record of achievement.

“I expect her to add significant value to the board and the company as we continue to develop our pipeline and grow our business.”

23rd February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics